Skip to main content
SpringerLink
Log in

Xpert assay more cost effective than sputum smear for TB

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. acid-fast bacilli

Reference

  • Cowan JF, et al. Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States. Clinical Infectious Diseases 64: 482-489, No. 4, 15 Feb 2017. Available from: URL: http://doi.org/10.1093/cid/ciw803

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xpert assay more cost effective than sputum smear for TB. PharmacoEcon Outcomes News 772, 36 (2017). https://doi.org/10.1007/s40274-017-3784-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3784-3

Search

Navigation